{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.15","value":"-40.3"},{"groupId":"OG001","spread":"23.37","value":"-32.3"},{"groupId":"OG002","spread":"21.44","value":"-40.5"}]}],"title":"Physician Assessment of DA-Week 76 (n=108, 61, 32)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.32","value":"-39.5"},{"groupId":"OG001","spread":"25.54","value":"-31.0"},{"groupId":"OG002","spread":"27.51","value":"-34.0"}]}],"title":"Physician Assessment of DA-Week 128 (n=79, 47, 18)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.49","value":"-27.5"},{"groupId":"OG001","spread":"25.52","value":"-27.5"},{"groupId":"OG002","spread":"24.11","value":"-27.6"}]}],"title":"Patient Assessment of DA-Week 76 (n=108, 61, 32)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.40","value":"-27.9"},{"groupId":"OG001","spread":"29.72","value":"-19.3"},{"groupId":"OG002","spread":"25.17","value":"-27.6"}]}],"title":"Patient Assessment of DA-Week 128 (n=79, 47, 18)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.10","value":"-25.1"},{"groupId":"OG001","spread":"24.24","value":"-27.3"},{"groupId":"OG002","spread":"23.49","value":"-23.4"}]}],"title":"Patient Assessment of Pain-Week 76 (n=108, 61, 32)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.35","value":"-24.2"},{"groupId":"OG001","spread":"28.85","value":"-18.0"},{"groupId":"OG002","spread":"22.99","value":"-22.3"}]}],"title":"Patient Assessment of Pain-Week 128 (n=79, 47, 18)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"32"}],"units":"Participants"}],"description":"Physician's and Patient's assessments of DA assessed using a VAS that ranged from 0 to 100 mm, where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).","dispersionType":"Standard Deviation","groups":[{"description":"Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.\n\nReceived 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.\n\nReceived 4 mg LY3009104 QD in Part C.\n\nReceived 4 mg LY3009104 QD in Part D.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"4 mg LY3009104 QD - Parts C and D"},{"description":"Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.\n\nReceived 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.\n\nReceived 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.\n\nDose escalation criteria: ≥6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.\n\nReceived 4 mg LY3009104 QD in Part D.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D"},{"description":"Received 8 mg LY3009104 QD in Parts A, B and C.\n\nReceived 4 mg LY3009104 QD in Part D.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D"}],"paramType":"MEAN","populationDescription":"All participants who received study drug in Parts C and D and had physician's and participant's assessments of disease activity and pain evaluated at analysis time points. LOCF was used to impute missing post-baseline values.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 76 and 128","title":"Mean Change From Baseline to Weeks 76 and 128 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain","type":"SECONDARY","unitOfMeasure":"units on a scale"}